GREY:DGCRF - Post by User
Comment by
CUR2004on Oct 07, 2011 12:45pm
212 Views
Post# 19130161
RE: More on PSA; WaPo
RE: More on PSA; WaPoIs it a good or bad news?
Do you think Gen-Probe do change on his FDA submission in response to this. Could they change their procedure to not consider PSA test?
For the actual submission tio FDA, less P.S.A. = less biopsy = less use of PCA3 test
“Unfortunately, the evidence now shows that this (P.S.A.) test does not save men’s lives,” said Dr. Virginia Moyer, a professor of pediatrics at Baylor College of Medicine and chairwoman of the task force. “This test cannot tell the difference between cancers that will and will not affect a man during his natural lifetime. We need to find one that does.”
But this could be really good...
- In early March 2010, the clinical utility of PCA3 was confirmed in two large worldwide studies, conducted in a subset of about 2,400 patients from GlaxoSmithKline’s REDUCE trial of dutasteride. The studies were presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU) in San Francisco. The results demonstrated that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.